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Pulmonic Stenosis in Dogs: Balloon Dilation
Improves Clinical Outcome
M. Stafford Johnson, M. Martin, D. Edwards, A. French, and W. Henley
Medical records of 81 dogs with severe pulmonic stenosis from 2 referral centers were examined retrospectively. Forty dogs
underwent balloon valvuloplasty (BV), which was performed by 1 operator, whereas 41 did not. The mean age at latest follow-up
was 41.5 months. A statistical comparison of the clinical outcome and survival was performed. Dogs revealing clinical signs at
presentation showed a 16-fold increase in risk of death compared with asymptomatic dogs (P , .001). Statistical analyses dem-
onstrated that an increase of 1 mm Hg in transstenotic pressure gradient (PG) at presentation was associated with a 3% increase
in hazard rate (P , .001). Thirty-seven dogs survived BV with a median reduction in PG of 46%. The median preoperative PG
was 120 mm Hg, and median PG 24 hours postoperatively was 55 mm Hg with a median of 55 mm Hg 6 months post-BV. Twenty
(49%) of the non-BV (NBV) dogs remained asymptomatic at last follow-up. Fourteen (34%) of the NBV dogs died or were
euthanized because of heart disease related to pulmonic stenosis. Twelve of these dogs died suddenly, whereas only 1 of the BV
dogs died suddenly. After adjusting for PG, clinical signs at presentation, and age, BV or dilation was associated with a 53%
reduction in hazard rate (P 5 .005). This study indicates that BV, when performed by an experienced operator, appears to be
successful both in alleviating clinical signs and in prolonging survival in dogs with severe pulmonic stenosis.
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Pulmonic stenosis generally is considered the third mostcommon congenital cardiac defect in dogs.1 Dogs with
a Doppler-derived pressure gradient (PG) over 80 mm Hg
have been classified as having severe stenosis and are at
risk for developing clinical signs of exercise intolerance,
syncope, or sudden death.1 Balloon valvuloplasty (BV) cur-
rently is the best available therapy for this condition and
has been recommended in severe cases with moderate or
severe right ventricular hypertrophy (RVH) or when af-
fected dogs are symptomatic.
Only 1 previous report2 compared clinical signs and sur-
vival times in dogs undergoing BV (n 5 18) with those
that did not (NBV, n 5 6). The investigators identified a
reduction in clinical signs in dogs undergoing BV but did
not demonstrate a significant difference in survival times
between the 2 groups. Another study compared survival in
dogs undergoing BV (n 5 25), NBV (72), and dogs un-
dergoing open surgical repair of their pulmonic stenosis
(30) and found increased survival over 2 years in BV dogs
versus NBV dogs.1 Others have described the results of BV
without comparison with an NBV population.3–8 This study
compares the progression of clinical signs and survival in
40 BV dogs with 41 NBV dogs.
Materials and Methods
Medical records of the Veterinary Cardiorespiratory Center (VCRC)
and the University of Edinburgh (UE) between January 1993 and Jan-
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uary 2003 were searched for cases of severe pulmonic stenosis. All
dogs were presented either for investigation of an asymptomatic heart
murmur or for clinical signs of exercise intolerance, collapse, or both.
Inclusion criteria for the study included the presence of severe pul-
monic stenosis with a PG . 80 mm Hg diagnosed on Doppler echo-
cardiography. Dogs with concurrent cardiac defects causing cardio-
megaly or clinical signs were excluded, but dogs with defects that were
not considered clinically relevant were included. Dogs with tricuspid
valve regurgitation (TVR) were included.
A total of 88 dogs were selected, but 7 were excluded. Specific
reasons for exclusion from the study included concurrent clinically
significant cardiac defects (n 5 6) and absence of adequate follow-up
(1). Three dogs had concurrent patent ductus arteriosus, 1 had con-
current moderate aortic stenosis, and 2 had moderate-sized ventricular
septal defects. Evidence of left ventricular hypertrophy or dilatation
was present in all 6 dogs.
Echocardiographyb was performed in a standard manner from both
right and left parasternal views at both centers.9 The PG was assessed
from the right parasternal short axis and left cranial parasternal views.
No attempt was made to distinguish dogs with hypoplasia of the an-
nulus from dogs without hypoplasia. Also, the presence of commis-
sural fusion of the pulmonary valves versus thickened immobile valve
leaflets was not recorded in this retrospective study. Data were re-
corded as subvalvular, valvular, or supravalvular stenosis. Subvalvular
stenosis was defined as fixed rather than dynamic subvalvular obstruc-
tion. More proximal (midventricular) obstruction or double-chamber
right ventricle was not present in any of these dogs. The presence of
pulmonic or TVR was noted in each dog. The degree of RVH was
recorded as mild, moderate, or severe. Mild hypertrophy was defined
as subjectively increased right ventricular wall thickness with absence
of paradoxical motion of the interventricular septum on the right para-
sternal short-axis view. Moderate hypertrophy was defined as mild
paradoxical motion of the interventricular septum. Severe RVH was
defined as marked paradoxical motion of the septum on this view.
BV was advised in all dogs with severe stenosis regardless of the
morphologic appearance of the stenosis and whether hypoplasia of the
annulus was present. Dogs undergoing BV were treated with beta
blockers (atenolol 1 mg/kg PO q12h) for at least 2 weeks before BV.
BV was performed via the left jugular vein as described in earlier
reports by using fluoroscopic guidance.4–7,10 A balloon with a mean
diameter of 1.33 (range, 1.2–1.5) times the diameter of the pulmonary
valve annulus as measured on angiography was used to perform bal-
loon dilation. Beta blockers were administered for a minimum of 6
months after BV until the initial revisit was scheduled. Drug therapy
was ceased at that time unless the results of BV were considered un-
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Table 1. Breeds affected with severe pulmonic stenosis
in this series.
West Highland White Terrier
Cocker Spaniel
Labrador Retriever
Bulldog
Cavalier King Charles Spaniel
Bullmastiff
Yorkshire Terrier
German Shepherd Dog
Boxer
Crossbreeds
10
8
8
7
6
5
5
4
3
3
Shih Tzu
Border Terrier
Fox Terrier
Miniature Schnauzer
Rough Collie
3
2
2
2
2
Border Collie, Bichon Frise, French Bulldog,
Parson Russell Terrier, Lurcher, Newfoundland,
Pekingese, Great Pyrenees, Staffordshire Bull
Terrier, Soft Coated Wheaton Terrier, Whippet 1 each breed
satisfactory and there was evidence of ongoing dynamic right ventric-
ular outflow obstruction because of persistent RVH.
In Bulldogs, in addition to the above procedures, coronary angi-
ography via the femoral artery was carried out before BV to identify
dogs with an aberrant coronary artery associated with subvalvular ste-
nosis in this breed. This abnormality would represent a contraindica-
tion to BV if identified.
The decision not to perform BV was dictated by the owners, usually
because of financial reasons. Some of these dogs were maintained long
term on atenolol 1 mg/kg PO q12h. NBV dogs were rechecked an-
nually whenever possible, and echocardiography was repeated. For
dogs that were not returned, follow-up was performed via telephone
conversation with the owners and primary veterinary surgeons. Long-
term follow-up was defined as follow-up of 6 months or more.
Statistics
A preliminary examination of the data used frequency tables and
the mean plus range for different variables. Cox regression analysis
was used to determine any association between time to death associ-
ated with heart failure (measured from the time of presentation until
death from heart failure, including sudden death or euthanasia asso-
ciated with heart failure) and BV, before and after adjusting for po-
tential risk factors including PG, RVH, clinical signs, sex, and age.11
PG, RVH, and clinical signs all were measured at the time of presen-
tation, whereas BV was considered a time-dependent variable with
dogs treated after presentation contributing time at risk to both the
treatment (BV) and the nontreatment (NBV) groups. In addition, a
binary variable indicating whether the dog had ever been treated with
beta blockers was considered for inclusion in the Cox regression anal-
ysis.
Variables were selected for inclusion in the model if they signifi-
cantly improved the fit (likelihood ratio chi-square statistic P , .05).
Two-way interaction terms were tested between all main-effect vari-
ables. The relationship between survival time and treatment (BV), after
adjusting for other risk factors, was displayed with plots similar to
Kaplan-Meier curves but for time-dependent variables.12 Smoothing
splines were used to explore the functional form of the relationship
between time to death associated with heart failure and the continuous
variables (age and PG), after accounting for confounding from other
variables.c The fit of the selected Cox regression model13was assessed
by plotting deviance residuals against time to identify poorly fitting
points.12
Results
Sixty-three dogs from the VCRC and 18 dogs from the
UE were included in the study. All 40 dogs that underwent
BV were selected from the VCRC and had BV performed
by a single experienced operator (M.M.). The remaining 41
dogs did not undergo BV. Thirteen of these dogs were
maintained long term on atenolol 1 mg/kg PO q12h.
TVR varying from mild to severe was identified in 32
dogs (39%). Nineteen were from the NBV group and 13
were from the BV group. Other additional cardiac defects
were noted in 8 dogs. Five had a suspected patent foramen
ovale. These were diagnosed during right ventricular an-
giography preceding BV when trivial right-to-left interatrial
shunting was observed. No atrial septal defect was apparent
on 2-dimensional echocardiographic examination in these
dogs. Two dogs had a small patent ductus arteriosus, and
1 had a small ventricular septal defect with concurrent mild
subaortic stenosis.
Three Bulldogs were diagnosed with subvalvular steno-
sis, and 1 Cocker Spaniel had supravalvular stenosis. The
remainder had valvular stenosis. Three Bulldogs underwent
BV. The first, performed early in the series, did not undergo
coronary angiography and died during BV because of the
unrecognized presence of an aberrant coronary artery that
ruptured. In the remaining 2 dogs, an aberrant coronary
artery was not identified and BV was performed success-
fully.
Twenty-six different breeds, including crossbreeds, were
represented (Table 1). The West Highland White Terrier
was most commonly represented, followed by the Cocker
Spaniel, Labrador Retriever, Bulldog, and Cavalier King
Charles Spaniel. Sex distribution was 39 females (48%) and
42 males (52%).
Although the majority of dogs were younger than 12
months old at first presentation, the age distribution of the
study population skewed greatly to the right, with a small
number of dogs much older than the rest.
Twenty-six dogs (32%) were asymptomatic at presenta-
tion and have remained so at last follow-up at a median
age of 50 months (range, 5–144 months). Of these, 20 were
from the NBV group and 6 were from the BV group. Me-
dian PG for this population was 90 mm Hg (range, 80–170
mm Hg).
Forty-two dogs (52%) were symptomatic with exercise
intolerance, syncope, or both. Thirty-three were from the
BV group and 9 were from the NBV group. The median
age of onset of clinical signs was 12 months (range, 2–70
months). Age of onset varied between the 2 populations,
with BV dogs showing signs at a median age of 6 months
and NBV dogs at 12 months. Median PG for symptomatic
dogs was 110 mm Hg (range, 80–200 mm Hg). The median
age at last follow-up was 28 months (range, 3–120 months).
Sudden death was noted in 13 dogs (16%). One occurred
2 months post-BV, whereas 12 occurred in the NBV group.
These are described later. Median PG for dogs experiencing
sudden death was 150 mm Hg (range, 140–200 mm Hg).
Thirty-seven dogs survived BV and 3 died during the
procedure. In the 37 surviving dogs, a median reduction in
PG of 46% was observed. The median preoperative PG was
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Fig 1. A comparison between BV dogs and NBV dogs at presentation and at last follow-up.
120 mm Hg, and median PG 24 hours postoperatively was
55 mm Hg with a median of 55 mm Hg at 6 months post-
BV.
Long-term follow-up was available for the 37 surviving
BV dogs, and the median age at last follow-up was 32
months (range, 12–96 months). Of these 37 dogs, 30 be-
came asymptomatic and 3 remained asymptomatic (range,
12–94 months). One of the dogs that became asymptomatic
developed right-sided congestive heart failure 8 years after
BV at 10 years and was euthanized at that time. Of the
remaining 4 dogs, 1 had continuing right-sided congestive
heart failure and died 4 months post-BV, 1 experienced res-
tenosis and had ongoing right heart failure until euthanasia
at 18 months post-BV, 1 had ongoing syncopal episodes
with sudden death after 2 months, and 1 died of unrelated
causes after 4 months.
Follow-up was available for all 41 NBV dogs with a
median age at last follow-up of 46 months. Twenty of these
dogs (49%) remained asymptomatic at this time, and 14 of
the symptomatic dogs (34%) died or were euthanized be-
cause of heart disease related to pulmonic stenosis. Of these
dogs, 1 died of right heart failure, 1 was euthanized because
of severe clinical signs, and the remaining 12 died suddenly
with (n 5 8) or without (4) previous clinical signs. Eight
dogs demonstrated signs of collapse before death. Death
occurred at a median age of 9 months for these 12 dogs
(range, 3–65 months). The clinical features of BV and NBV
are compared in Figure 1.
Table 2 shows the univariable Cox regression models
used to assess associations between individual risk factors
and time to death from heart failure. When considered in-
dependently of other risk factors, BV did not have a sig-
nificant treatment effect (P 5 .48). The significant risk fac-
tors from the univariable models were PG, TVR, RVH, and
clinical signs (including congestive heart failure) at presen-
tation (P 5 .001, .019, .002, and .010, respectively). Two
dogs with BV had missing values for clinical signs at pre-
sentation and were therefore excluded from the correspond-
ing model. Age, sex, and use of beta blockers were not
significantly associated with survival time (P 5 .330, .057,
and .620, respectively). Although age was nonsignificant as
a linear effect in the univariable analysis, no assessment
was made of nonlinear effects at this stage (see below).
Table 3 shows the final multivariable Cox regression
model for risk factors associated with death from heart fail-
ure. An increase of 1 mm Hg in PG at presentation was
associated with a 3% increase in hazard rate (P , .001).
Dogs revealing clinical signs at presentation had a 16-fold
increase in risk of death compared with asymptomatic dogs
(P , .001). The relationship between age at presentation
and risk of death associated with heart failure was assessed
by fitting a multivariable Cox regression model with age
represented by a smoothing spline. This analysis showed
that age had a nonlinear relationship with risk (P , .05):
Risk decreased with age up to approximately 24 months,
after which risk started to increase with age (Fig 2). The
plot suggests that age has an approximately quadratic re-
lationship with risk of heart failure, and it was included in
this form in the final multivariable model. After adjusting
for PG, clinical signs at presentation, and age, BV was as-
sociated with a 53% reduction in hazard rate (P 5 .005).
Figure 3a,b show separate survivor curves for time to death
from heart failure before and after adjustment for the risk
factors in the multivariable model. These plots illustrate
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Table 2. Univariate results for risk factors calculated by Cox regression analysis.
Risk Factor
No. of
Dogs Coefficient
Standard
Error
Hazard
Ratio
Lower
Confidence
Interval
Upper
Confidence
Interval P value
Age
Beta blockers
BV
PG
Male dogs
Clinical signs
TVR
RVH
80a
80a
80a
80a
80a
78a,b
80a
78a,b
20.017
20.101
20.147
0.020
0.404
1.190
0.461
1.450
0.017
0.202
0.209
0.006
0.212
0.460
0.197
0.233
0.98
0.90
0.86
1.02
1.50
3.27
1.59
4.28
0.95
0.61
0.57
1.01
0.99
1.33
1.08
1.71
1.02
1.34
1.30
1.03
2.27
8.06
2.33
10.70
.330
.620
.480
,.001
.057
.010
.019
.002
BV, balloon valvuloplasty; PG, pressure gradient at presentation; TVR, tricuspid valve regurgitation; RVH, right ventricular hypertrophy.
a One dog whose age was not included at BV was excluded from the Cox regression analysis.
b Two dogs whose clinical signs were not included at presentation and RVH were excluded from the corresponding univariable Cox regression
models.
Table 3. Cox regression model indicating that balloon valvuloplasty (BV), pressure gradient (PG) at presentation, clinical
signs at presentation, age, and the quadratic function of age (Age2) were significantly associated with survival time of dogs
with severe pulmonary stenosis.
Coefficient
Standard
Error
Hazard
Ratio
Lower
Confidence
Interval
Upper
Confidence
Interval P value
Age
Age2
BV
PG
Clinical signs
20.188
0.003
20.750
0.025
2.746
0.058
0.001
0.267
0.007
0.690
0.828
1.003
0.472
1.025
15.575
0.740
1.001
0.280
1.012
4.029
0.927
1.004
0.797
1.039
60.205
.001
.002
.005
,.001
,.001
how the beneficial effect of BV on survival time becomes
apparent after adjustment for the confounding variables. As
before, 2 dogs were excluded from the final multivariable
model because of missing data for clinical signs at presen-
tation.
Although both TVR and RVH were significant risk fac-
tors in the univariable analysis, neither was significantly
associated with survival time in the multivariable analysis
after adjustment for PG (P 5 .793 and .560, respectively).
An indicator variable for institute was included in the mul-
tivariable model after adjusting for BV and was not found
to be significant (P 5 .41).
Plotting deviance residuals against time identified 2 dogs
that were poorly fitted by the selected Cox regression mod-
el. Both died within 1 month of presentation, with 1 un-
dergoing BV and the other untreated. Refitting the final
model after excluding these 2 dogs did not have a material
impact on the model coefficients.
Discussion
One previously published paper compared a small pop-
ulation of BV dogs and NBV dogs and demonstrated a
reduction in clinical signs but not increased longevity in
dogs after BV.2 In our study, comparing a larger population
of dogs, we documented an improvement in clinical signs
and survival in dogs undergoing BV, with a 53% reduction
in hazard rate (P 5 .005). Additionally, there was only 1
sudden death in the BV group compared with 12 in the
NBV group.
Only 1 experienced operator from 1 center performed
BV to minimize variability in results because of operator
experience or technique. Records of 18 additional NBV
dogs from another center (UE) were used to balance the
numbers in the 2 populations. The NBV dogs from both
centers did not undergo BV because of owner constraints
and were not explicitly selected according to the presence
or absence of clinical signs or echocardiographic appear-
ance of the stenosis. However, it is apparent from the data
that dogs with clinical signs were more likely to receive
BV, which, if not considered in the analysis, could have led
to underestimation of the benefits of BV: 85% of the BV
dogs were symptomatic on presentation compared with
51% of the NBV dogs. Owners whose dogs display clinical
signs caused by pulmonic stenosis may be more likely to
elect an invasive procedure for their dogs than are owners
whose dogs display no outward signs of being affected.
Financial constraints are also a factor.
The inclusion in this study of data from 2 institutes with
all treated dogs from the same institute (VCRC) could have
resulted in confounding of the relationship between BV and
survival time. But because untreated dogs were represented
at both institutes, an assessment of the institute effect for
untreated dogs could be conducted, thus avoiding complete
confounding. The nonsignificant effect of institute suggest-
ed that untreated UE dogs and untreated VCRC dogs could
be combined into a single untreated category for both in-
stitutes. We were not able to assess whether the effect of
BV varied by institute, and the analysis of this study is
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Fig 2. Graphic representation of the functional form of age at pre-
sentation, modeled with smoothing splines in a multivariable Cox re-
gression model for risk of death associated with heart failure, including
sudden death, with time measured as number of months after first
presentation. The plot shows the smoothed, fitted log hazard and 95%
confidence intervals, with rug plots (vertical lines at the bottom of the
figure) representing the age at presentation of individual dogs, indi-
cating that the risk of death decreases with age at first and then in-
creases after 30 months.
Fig 3. Survivor curves comparing time to death associated with heart
failure, including sudden death for dogs treated with balloon valvu-
loplasty (BV), and dogs in the nontreatment group (NBV). (a) Without
adjustment for other variables. (b) Following adjustment of the model
for clinical signs, gradient pressure, and age at presentation. The cross-
es represent censoring times (ie, the times at which dogs were lost to
follow-up). The survivor curves are not displayed beyond 50 months
because of the small number of dogs followed up for this length of
time. No deaths were in the NBV group beyond 40 months, and only
2 deaths were in the BV group beyond 50 months.
based on the assumption that the BV treatment protocol at
the VCRC is sufficiently representative so that the estimat-
ed effect of BV can be generalized to other centers, in-
cluding the UE.
In observational studies, the above types of selection ef-
fects are common. We have tried to reduce their impact on
the estimated treatment effect by adjusting for measured
covariables such as age, PG, and clinical signs. Even so,
the risk of residual confounding from other unmeasured
variables remains.
The West Highland White Terrier, Labrador Retriever,
and Cocker Spaniel all were commonly presented breeds in
common with a previous UK study,2 and all are popular
breeds in the UK. No sex predisposition was identified, in
keeping with another study,14 but 2 other studies demon-
strated a male predisposition.2,3
TVR, varying from mild to severe, was seen in 39% of
dogs compared with 46% in another study.14 Associated
right atrial enlargement varied from mild to marked. Many
of these dogs may have represented concurrent tricuspid
valve dysplasia, which has been recognized in association
with pulmonic stenosis.1
A patent foramen ovale was diagnosed during right ven-
tricular angiography before performing BV. Contrast echo-
cardiography was not performed routinely in NBV dogs,
and some of these dogs also may have had a patent foramen
ovale, which was not detected.
It was not possible to classify the detailed nature of the
stenosis in this retrospective study. A recent study3 has
shown the value of differentiating between dogs with or
without hypoplasia of the pulmonary annulus before BV. A
better prognosis after BV may be given in dogs without
hypoplasia, and this finding may influence the decision to
perform BV. In the future, this factor should be taken into
consideration before undertaking BV.
It is important to perform coronary angiography in Bull-
dogs before BV. Failure to document the presence of an
aberrant coronary artery caused the death of the first Bull-
dog undergoing BV in our clinic.
In some dogs placed on atenolol before BV, PG de-
creased by the time of intervention. Whether a reduced PG
could be beneficial in NBV dogs on long-term atenolol still
is speculative.
Although the BV and NBV populations of dogs in this
study differed in some respects, the median PG at presen-
tation was similar for both groups. However, more dogs in
the NBV group (n 5 19) had TVR than did dogs in the
BV group (13). Dogs in the BV group developed clinical
signs at a younger age than did dogs in the NBV group.
The increased risk of death caused by severe pulmonic
stenosis in young dogs was not surprising, and an increase
of 1 mm Hg in PG at presentation was associated with a
3% increase in hazard rate. The most severely affected pups
are most likely to exhibit clinical signs or die of their con-
dition at a young age. The risk decreased over the first 30
months of life. Reasons for increased risk again after this
time period are unclear.
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The proportion of dogs that eventually becomes symp-
tomatic because of pulmonic stenosis is not known at this
time. Symptomatic dogs in general presented with a higher
median PG than did asymptomatic dogs. However, overlap
occurred between these 2 groups, and it is not possible to
determine from the presenting PG which individuals will
become symptomatic. Fourteen dogs in the NBV group, all
with PG below 100 mm Hg and with mild to moderate
RVH, have remained apparently asymptomatic for as long
as 84 months. It is likely that a proportion of these would
show increased exercise tolerance after BV, but in all in-
stances the owners have not perceived a problem. These
dogs are currently monitored primarily via telephone con-
tact with the owner.
The drop in PG post-BV was similar to that reported in
several previous studies.2,3,15 Hemodynamic improvement
and a reduction in clinical signs after BV has been docu-
mented previously in humans and dogs.8,16–19. Despite the
greater proportion of symptomatic dogs in the BV group at
presentation, this group improved symptomatically post-
BV. In this group, 15% of dogs were asymptomatic on pre-
sentation, increasing to 72% after successful BV. In the
NBV group, 49% presented as asymptomatic. Dogs in this
group were more likely to exhibit sudden death, with or
without previous clinical signs. Several dogs had been
scheduled for BV but died before the procedure could be
performed. In total, 12 dogs in the NBV group died sud-
denly versus 1 dog in the BV group.
The results of the final multivariable Cox regression
model showed that BV had a significant protective effect
on survival times. This treatment effect was not significant
in the univariable model because of the confounding effect
of the variable clinical signs at presentation: Dogs in the
BV group were more likely to have clinical signs at pre-
sentation than were dogs in the nontreatment group, and
clinical signs were associated with increased risk of heart
failure, thus counterbalancing the protective effect of BV.
Although this study found BV to be significantly protec-
tive for death associated with heart disease, the dogs in this
study were selected by convenience sampling. The esti-
mated protective treatment effect may have been influenced
by other unmeasured confounders. A randomized clinical
trial would provide the ‘‘gold standard’’ design for confirm-
ing the efficacy and clinical usefulness of BV as an inter-
vention to improve the survival of dogs with severe pul-
monic stenosis. In addition, some of the improvement in
survival time attributed to surgery may have been attrib-
utable to superior postdiagnosis management.
In this study, failures were defined as dogs that died or
were euthanized because of heart failure. However, eutha-
nasia is not an end-point determined exclusively by disease
pathology; it also will depend on factors that include clin-
ical status of the dog as well as financial constraints and
attitudes of the owner. The classification of 3 euthanized
dogs as equivalent to those dying naturally of heart failure
may have introduced some bias into the estimation of the
survival function and median survival time. However, any
bias in the estimate of the treatment effect is likely to be
negligible because of the small proportion of dogs that was
euthanized. An alternative approach would have been to
censor the euthanized dogs, but this would have introduced
a form of informative censoring and would have reduced
the power of the study.20
Ideally, all dogs should be followed until the point of
death, whether by natural causes or euthanasia. It is not
currently known what proportion of BV dogs may ulti-
mately die of their heart disease in comparison with NBV
dogs. To document such outcomes would require longer
follow-up of these dogs.
In conclusion, BV was associated with a 53% reduction
in hazard rate after adjustment for the significant risk fac-
tors, PG, age, and clinical signs at presentation, with only
1 sudden death in the BV group compared with 12 in the
NBV group. This study has shown that BV, when per-
formed by an experienced operator, appears to be successful
both in alleviating clinical signs and in prolonging survival
in dogs with severe pulmonic stenosis.
Footnotes
a Ewey DM, Pion PD, Hird DW. Survival in treated and untreated dogs
with congenital pulmonic stenosis [abstract]. J Vet Intern Med 1992;
6:114
b Esaote Biomedica Challenge 7000 with 2.5–7.5 MHz mechanical
probes; Esaote Biomedica UK Ltd, Huntingdon, Cambridgeshire, UK
c S-PLUS 6 (Insightful 2001) Insightful Corp, Seattle, WA
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